Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

CLINICAL AND IMMUNOLOGICAL EFFECTS OF RECOMBINANT LEUKOCYTE A INTERFERON IN 8 PATIENTS WITH ADVANCED CANCER JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION Horning, S. J., Levine, J. F., MILLER, R. A., Rosenberg, S. A., Merigan, T. C. 1982; 247 (12): 1718-1722

Abstract

The clinical and immunologic effects of a biosynthetic human leukocyte interferon, recombinant leukocyte A interferon (IFL-rA), are reported in eight patients with advanced cancer. Single escalating doses from 3 X 10(6) units to 198 X 10(6) units were given by intramuscular injection in a phase I study. Major toxic effects included pyrexia, fatigue, myalgia, and headache. Data on the effects of IFL-rA on lymphocyte subpopulations and peripheral blood mononuclear-cell surface beta 2-microglobulin are presented. Four of eight patients had objective tumor regression, indicating that further investigation of this biologically active material is warranted.

View details for Web of Science ID A1982NG35000017

View details for PubMedID 6174742